Tesamorelin: FDA-Approved GHRH Analog, Lipodystrophy & GH Research

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is Tesamorelin?

Tesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH) that has received FDA approval for the reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients with lipohypertrophy. It consists of the 44-amino-acid sequence of human GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus, which confers resistance to enzymatic degradation and extends biological activity compared to native GHRH.

Tesamorelin is unique among GHRH analogs as the only one with full FDA approval for a body composition indication. This regulatory status provides a level of clinical validation — including large-scale safety data — that exceeds most other growth hormone secretagogues in the research peptide space. Its mechanism is physiological: tesamorelin stimulates the pituitary to produce its own growth hormone in a pulsatile manner, rather than replacing GH with exogenous hormone.

How Tesamorelin Works: Mechanism of Action

• GHRH receptor agonism — Tesamorelin binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary, activating the Gs-adenylyl cyclase-cAMP-PKA signaling cascade. This triggers growth hormone synthesis, storage, and pulsatile secretion — the same pathway activated by endogenous GHRH and by CJC-1295.
• Physiological GH pulsatility — Unlike exogenous GH administration (which produces non-physiological, flat GH levels), tesamorelin stimulates the pituitary to release GH in its natural pulsatile pattern. This pulsatility is important because GH pulse amplitude and frequency differentially regulate downstream signaling, including the ratio of lipolytic to anabolic effects.
• IGF-1 elevation — Through downstream GH signaling, tesamorelin increases IGF-1 levels. Clinical trials documented mean IGF-1 increases of 80–100 ng/mL from baseline — bringing levels into the upper normal range without exceeding physiological limits in most subjects.
• Subject to negative feedback — Because tesamorelin works through the physiological GH axis, it remains subject to somatostatin-mediated negative feedback. This self-limiting mechanism prevents excessive GH production and is a safety advantage over exogenous GH administration.
• Visceral fat-specific lipolysis — GH has well-documented lipolytic effects, and tesamorelin-stimulated GH secretion preferentially mobilizes visceral (trunk) adipose tissue. The mechanism involves GH-mediated activation of hormone-sensitive lipase (HSL) in visceral adipocytes, which have higher GH receptor density than subcutaneous fat depots.

Clinical Trial Data: HIV Lipodystrophy

Pivotal Trials

Tesamorelin’s FDA approval was based on two phase III randomized, double-blind, placebo-controlled trials enrolling over 800 HIV-infected patients with excess abdominal fat:

• Trunk fat reduction — Tesamorelin 2 mg daily subcutaneous injection reduced trunk fat by approximately 15–18% from baseline at 26 weeks, as measured by CT scan. Placebo groups showed no significant change.
• Visceral adipose tissue (VAT) — VAT area decreased by approximately 15–20% in the tesamorelin group. VAT is the adipose depot most strongly associated with metabolic risk.
• Patient-reported outcomes — Significant improvements in body image distress scores and trunk appearance satisfaction.
• Metabolic parameters — Triglycerides decreased significantly. No worsening of glucose control at 26 weeks, though longer-term data showed modest increases in fasting glucose and HbA1c in some patients (see safety section).

Extension Studies

Long-term extension data (up to 2 years) demonstrated sustained VAT reduction with continued treatment, with reversal of fat loss upon treatment discontinuation — consistent with the finding that chronic treatment is needed to maintain benefits.

MASH/NASH and Liver Fat Research

An exciting emerging application for tesamorelin is the reduction of hepatic steatosis (liver fat). HIV-associated lipodystrophy often includes non-alcoholic fatty liver disease, and clinical studies have documented that tesamorelin:

• Reduced hepatic fat fraction by approximately 30–37% as measured by MRI-PDFF (proton density fat fraction)
• Improved liver fibrosis markers in subjects with MASH (metabolic dysfunction-associated steatohepatitis)
• Decreased hepatic de novo lipogenesis, suggesting a mechanism beyond simple GH-mediated lipolysis

Given the growing prevalence of MASH and the lack of approved treatments with substantial liver fat reduction data, tesamorelin’s hepatic effects have generated significant research interest extending beyond the HIV population.

Cognitive Aging Research

A clinical trial conducted at the University of Washington investigated tesamorelin’s effects on cognitive function in healthy older adults (60–75 years) with age-related cognitive decline. The rationale was based on the known decline of GH and IGF-1 with aging and the documented role of IGF-1 in synaptic plasticity and neuronal health.

The study reported:

• Improvements in executive function and verbal memory in tesamorelin-treated subjects compared to placebo
• Increased IGF-1 levels correlated with cognitive improvements
• Effects were specific to cognition rather than general mood or energy

While this is a single study with a modest sample size, it has generated interest in the potential cognitive applications of restoring physiological GH secretion in aging populations.

Comparison with Other GH Secretagogues

Compound	Mechanism	Half-life	Regulatory Status
Tesamorelin	GHRH analog	~26 min	FDA-approved (lipodystrophy)
Sermorelin	GHRH(1-29)	~10 min	Previously FDA-approved (pediatric GH deficiency)
CJC-1295 No DAC	Modified GHRH(1-29)	~30 min	Research use
CJC-1295 with DAC	Modified GHRH + albumin binding	~6–8 days	Research use
Ipamorelin	GHS-R agonist (ghrelin mimetic)	~2 hours	Research use

For a comprehensive comparison of growth hormone secretagogue research, see our CJC-1295 & Ipamorelin Research Guide and Sermorelin Research Guide.

Dosing

Context	Dose	Route	Frequency
FDA-approved (lipodystrophy)	2 mg	Subcutaneous (abdomen)	Once daily
Clinical trials (liver fat)	2 mg	Subcutaneous	Once daily for 12 months
Cognitive study	1 mg	Subcutaneous	Once daily for 20 weeks

Reconstitution and Handling

• Storage — Lyophilized tesamorelin at -20°C (research) or 2–8°C (pharmaceutical formulation)
• Reconstitution — Reconstitute with sterile bacteriostatic water. As a larger peptide (44 amino acids plus modification), reconstitute gently to avoid denaturation.
• Stability — Reconstituted solution stable approximately 14–21 days at 2–8°C

Safety Profile

Tesamorelin’s clinical safety data from FDA-reviewed trials provides one of the strongest safety records in the GH secretagogue class:

• Most common adverse effects — Injection site reactions (erythema, pruritus, pain) in approximately 9% of patients. Arthralgia (joint pain) in approximately 6%.
• Glucose metabolism — Modest increases in fasting glucose and HbA1c have been observed with long-term use, consistent with GH’s known diabetogenic effects. Blood glucose monitoring is part of the approved prescribing guidelines.
• Fluid retention — Peripheral edema and carpal tunnel syndrome have been reported at low rates, consistent with GH-related fluid retention.
• IGF-1 monitoring — IGF-1 levels should be monitored, with dose adjustment if levels exceed the age-adjusted normal range.
• Cancer considerations — Theoretically, GH/IGF-1 elevation could promote tumor growth. Clinical trials excluded patients with active malignancy, and long-term cancer surveillance data is limited.
• Reversibility — Fat loss effects reverse upon discontinuation, confirming that ongoing treatment is required.

Summary

Tesamorelin is the only FDA-approved GHRH analog for a body composition indication, providing a level of clinical validation that is unique among growth hormone secretagogues. Its physiological mechanism — stimulating endogenous, pulsatile GH release while maintaining negative feedback — represents a fundamental advantage over exogenous GH. Clinical data demonstrates significant visceral fat reduction, liver fat improvement, and potential cognitive benefits in aging populations. As the field continues to explore the therapeutic potential of restoring physiological GH secretion in aging and metabolic disease, tesamorelin serves as the clinical benchmark against which investigational GHRH analogs are measured.

View Tesamorelin in our research catalog. Related GH secretagogues: Sermorelin, CJC-1295 No DAC, and Ipamorelin.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Dhillon	2011	Review	Growth hormone and tesamorelin in HIV-associated lipodystrophy management	PMC3218714
Stanley et al.	2014	RCT	Tesamorelin effects on visceral and liver fat in HIV patients	PMC4363137
Fourman et al.	2020	RCT	Tesamorelin effects on NAFLD in HIV (randomized, double-blind, multicenter)	PMC6981288
Stanley et al.	2019	RCT	Tesamorelin decreases muscle fat and increases muscle area in HIV adults	PMC6766405
Fourman et al.	2020	Transcriptomic	Tesamorelin effects on hepatic transcriptomic signatures in HIV-NAFLD	PMC7455119
Makimura et al.	2015	Predictive	Predictors of treatment response to tesamorelin in HIV patients	PMC4601733
Stanley et al.	2017	Clinical	Visceral fat reduction with tesamorelin and improved liver enzymes	PMC5633509
Makimura et al.	2012	RCT	Metabolic effects of GHRH in obese subjects with reduced GH secretion	PMC3513535

This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.